Ephrins

ephrin-B1

ephrin-B1

ephrin-B2

ephrin-B2

ephrin-B3

ephrin-B3

Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K D =610 pM). Ifabotuzumab induces tumor cell apoptosis , activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic

Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K D =610 pM). Ifabotuzumab induces tumor cell apoptosis , activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic

Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K D =610 pM). Ifabotuzumab induces tumor cell apoptosis , activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic

LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC 50 of 0.079 µM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the